Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc. (MYMD)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2024
Reporting Period: Immediate event reporting regarding a corporate action effective February 14, 2024.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
The primary material change reported is a 1-for-30 reverse stock split of the Company's common stock.
- Share Count Reduction: Outstanding shares decreased from 62,749,125 to approximately 2,091,638 shares.
- Authorized Shares: Reduced from 500,000,000 to 16,666,666 shares.
- Effective Time: 4:05 p.m. Eastern Standard Time on February 14, 2024.
- Trading Resumption: Trading on a split-adjusted basis began on February 15, 2024, on The Nasdaq Capital Market under the symbol "MYMD".
- Fractional Shares: No fractional shares were issued; fractional amounts were rounded up to the nearest whole share.
Guidance, Outlook, and Contingencies
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. However, it details specific adjustments to existing financial instruments:
- Warrants and Preferred Stock: Proportionate adjustments were made to exercise and conversion prices for outstanding warrants and Series F Convertible Preferred Stock. Specific provisions in the Series F Certificate of Designations may trigger further price reductions based on the "Event Market Price" 16 trading days post-split.
- Equity Incentive Plans: Share counts and exercise prices under the 2013, 2016, 2017, 2018, and 2021 Equity Incentive Plans were proportionally adjusted. Share counts were rounded down to the nearest whole share, and exercise prices were rounded up to the nearest whole cent.
- Stockholder Action: Stockholders holding physical certificates were instructed not to destroy them and to await instructions from the transfer agent (Securities Transfer Corporation) for exchange.
Investor Verification Checklist
- Verify the new CUSIP number for the stock: 62856X201.
- Confirm the adjusted number of shares held in brokerage accounts reflects the 1-for-30 ratio (rounded up for fractions).
- Review the terms of any held warrants or convertible preferred stock for potential secondary price adjustments triggered by the "Event Market Price" clause.
- Ensure physical stock certificates have not been destroyed pending instructions from the transfer agent.